Owing to the rapid introduction of molecular diagnostics for MERS-CoV, the EQA program consisted of two phases. In the first phase, the participants performed a self-validation of their methods using known concentrations of distributed viral material; in the second phase, the participants performed a blind assessment using unknown concentrations of the distributed viral material. 